Klivira
Request demo

Optimizing Infectious Disease Prior Authorization Automation

Klivira's platform delivers end-to-end infectious disease prior authorization automation, specifically addressing the complexities of high-cost therapies and urgent treatment timelines.

For revenue cycle directors and prior authorization coordinators in infectious disease, managing prior authorizations for complex and high-cost treatments like antivirals, antifungals, and Outpatient Parenteral Antibiotic Therapy (OPAT) presents significant operational challenges. Manual workflows often lead to delays, increased administrative burden, and potential impacts on patient access to critical care. Automating these processes is essential for efficiency and patient outcomes.

The Unique Prior Authorization Challenges in Infectious Disease

Infectious disease (ID) prior authorizations are characterized by a high volume of complex, high-cost medications and therapies where timely approval is often critical. The manual process of verifying requirements, assembling detailed clinical documentation, and navigating payer-specific submission channels can significantly delay treatment initiation for conditions like HIV, Hepatitis C, and severe fungal infections, impacting antimicrobial stewardship efforts and patient recovery trajectories.

Common Prior Authorization Triggers in Infectious Disease

  • High-cost antivirals (e.g., HCV regimens, specific HIV therapies)
  • Novel antifungals for resistant infections
  • Outpatient Parenteral Antibiotic Therapy (OPAT)
  • Specialty biologics for chronic infections
  • Advanced diagnostic imaging for complex infectious processes

Klivira's Automated Workflow for Infectious Disease Prior Authorizations

Klivira integrates directly with EMRs to automate the entire prior authorization lifecycle, from initial requirement detection to approval write-back. This is particularly impactful for infectious disease, where the platform can pull specific FHIR resources such as MedicationRequest, DiagnosticReport, Condition, and Observation to build comprehensive documentation packets, ensuring payer criteria are met efficiently. Our system routes requests through the optimal channel—Da Vinci PAS, X12 278, or payer portals—to minimize manual intervention and accelerate decision times.

Key Automation Capabilities for ID Workflows

Our platform is engineered to address the specific needs of infectious disease prior authorization, enhancing both speed and accuracy. By leveraging industry standards and intelligent automation, we transform the historically manual process into a streamlined, electronic workflow that supports rapid patient access to necessary treatments and reduces administrative overhead.

Automated Steps Supporting ID Prior Authorization

  • EMR-side detection of PA requirements at order entry for antivirals, antifungals, and OPAT via CDS Hooks.
  • Automated assembly of clinical documentation from FHIR resources (MedicationRequest, DiagnosticReport, Condition, Observation) within the EMR.
  • Payer-specific submission routing via Da Vinci PAS API, X12 278, or provider portal API for pharmacy and medical benefits.
  • Real-time decision tracking and status updates pushed back to the EMR (e.g., Inbasket messages for Epic users).
  • Automated authorization number write-back to the EMR's order record upon approval.
  • Intelligent denial routing for ID-specific clinical necessity denials, including auto-appeal preparation.

Compliance and Standards for ID Prior Authorization Automation

Klivira's platform adheres to critical industry standards and regulatory mandates, ensuring that infectious disease prior authorization processes are not only efficient but also compliant. Our system incorporates Da Vinci CRD-style coverage requirement discovery and supports Da Vinci DTR for structured documentation. For submission, we utilize Da Vinci PAS and X12 278. Furthermore, our workflows are designed to respect the decision timeframes stipulated by CMS-0057-F for impacted payers, which is crucial for time-sensitive ID treatments.

Frequently asked questions

How does Klivira handle prior authorizations for high-cost antivirals?

Klivira detects PA requirements for high-cost antivirals at the point of order entry in the EMR. It then automatically assembles the necessary clinical documentation, including lab results and medication history, from FHIR resources. The request is submitted through the appropriate payer channel (e.g., Da Vinci PAS, X12 278, or payer portal), and status is tracked in real-time.

Can Klivira integrate with my EMR for infectious disease documentation?

Yes, Klivira offers robust EMR integration via SMART App Launch on FHIR for platforms like Epic, Cerner / Oracle Health, athenahealth, MEDITECH Expanse, and eClinicalWorks. This allows for automated extraction of ID-specific clinical notes, lab results, and medication history needed for PA submissions, minimizing manual data entry.

What happens if an infectious disease PA is denied?

Upon denial, Klivira parses the denial reason (e.g., X12 CARC/RARC codes) and intelligently routes the case. For many denials, it can auto-assemble an appeal packet based on payer specifications. If clinical judgment is required, the case is routed for human review or peer-to-peer scheduling, with timely-filing windows actively tracked to prevent lapses.

Does Klivira support prior authorization for Outpatient Parenteral Antibiotic Therapy (OPAT)?

Absolutely. Klivira's platform identifies OPAT orders requiring prior authorization at the time of order entry. It then automates the documentation assembly, drawing from relevant EMR data, and submits the request through the correct payer channel. This ensures timely approval for critical outpatient antibiotic regimens.

How does Klivira ensure compliance with federal PA rules like CMS-0057-F?

Klivira's workflow is designed to align with federal interoperability and prior authorization rules, including CMS-0057-F. For impacted payers (MA, Medicaid managed care, CHIP MCO, QHP-on-FFM), the system helps manage the 72-hour standard and 24-hour expedited PA decision timeframes, providing critical support for compliance.

Related coverage

Other infectious-disease prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo